Alliance Global analyst Scott Henry initiated coverage of Sensus Healthcare (SRTS) with a Buy rating and $7.50 price target Sensus sells the SRT-100/Vision medical device to deliver superficial radiation therapy for the treatment of oncological and non-oncological skin conditions, notes the analyst, who expects strong revenue growth for the SRT platform, particularly with new reimbursement codes in place for 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS: